Kemwell Biopharma has acquired Cirrus Pharmaceuticals Inc. Cirrus has development expertise in inhalation, parenteral, transdermal, topical and liquid dosage forms, and offers stand-alone analytical services including stability studies. Financial terms were not disclosed.   “Kemwell’s corporate objective is to build a leading global bio/pharmaceutical contract services company,” said Anurag Bagaria, chairman and managing director of Kemwell. “Cirrus will complement the existing...